Teva Pharmaceutical Industries (TEVA) Net Income towards Common Stockholders (2016 - 2026)

Teva Pharmaceutical Industries has disclosed Net Income towards Common Stockholders across 11 years of filings, most recently posting $366.0 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 71.83% year-over-year to $366.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 182.43% YoY) and the FY2025 annual result came in at $1.4 billion, up 171.12% from the prior year.
• Net Income towards Common Stockholders declined to $366.0 million in Q1 2026, from $466.0 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $466.0 million in Q4 2025 and troughed at -$2.1 billion in Q4 2022.
• A 5-year average of -$533.7 million and a median of -$506.0 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 111.53% — and 2025, when it surged 265.25%.
• Tracing TEVA's Net Income towards Common Stockholders over 5 years: stood at -$2.1 billion in 2022, then surged by 92.76% to -$154.0 million in 2023, then slumped by 83.12% to -$282.0 million in 2024, then jumped by 265.25% to $466.0 million in 2025, then fell by 21.46% to $366.0 million in 2026.
• Business Quant data shows TEVA's Net Income towards Common Stockholders at $366.0 million in Q1 2026, $466.0 million in Q4 2025, and $428.0 million in Q3 2025.